A personalized nomogram for predicting 3-year overall survival of patients with uterine carcinosarcoma in a tertiary care hospital in Southern Thailand
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
ObjectiveTo develop a nomogram for predicting 3-year overall survival (OS) and outcomes of surgically staged patients with uterine carcinosarcomas (UCS). MethodsThis retrospective study analyzed the clinicopathological characteristics, treatment data, and oncological outcomes of 69 patients diagnosed with UCS between January 2002 and September 2018. Significant prognostic factors for OS were identified and integrated to develop a nomogram. Concordance probability (CP) was used as a precision measure. The model was internally validated using bootstrapping samples to correct overfitting. ResultsThe median follow-up time was 19.4 months (range, 0.77-106.13 months). The 3-year OS was 41.8% (95% confidence interval [CI], 29.9-58.3%). The International Federation of Gynecology and Obstetrics (FIGO) stage and adjuvant chemotherapy were independent factors for OS. The CP of the nomogram integrating with body mass index (BMI), FIGO stage, and adjuvant chemotherapy was 0.72 (95% CI, 0.70-0.75). In addition, the calibration curves for the probability of 3-year OS demonstrated good agreement between the nomogram-predicted and observed data. ConclusionThe established nomogram using BMI, FIGO stage, and adjuvant chemotherapy accurately predicted the 3-year OS of patients with UCS. The nomogram was useful for patient counselling and deciding on follow-up strategies.
Abstract
ObjectiveTo develop a nomogram for predicting 3-year overall survival (OS) and outcomes of surgically staged patients with uterine carcinosarcomas (UCS). MethodsThis retrospective study analyzed the clinicopathological characteristics, treatment data, and oncological outcomes of 69 patients diagnosed with UCS between January 2002 and September 2018. Significant prognostic factors for OS were identified and integrated to develop a nomogram. Concordance probability (CP) was used as a precision measure. The model was internally validated using bootstrapping samples to correct overfitting. ResultsThe median follow-up time was 19.4 months (range, 0.77-106.13 months). The 3-year OS was 41.8% (95% confidence interval [CI], 29.9-58.3%). The International Federation of Gynecology and Obstetrics (FIGO) stage and adjuvant chemotherapy were independent factors for OS. The CP of the nomogram integrating with body mass index (BMI), FIGO stage, and adjuvant chemotherapy was 0.72 (95% CI, 0.70-0.75). In addition, the calibration curves for the probability of 3-year OS demonstrated good agreement between the nomogram-predicted and observed data. ConclusionThe established nomogram using BMI, FIGO stage, and adjuvant chemotherapy accurately predicted the 3-year OS of patients with UCS. The nomogram was useful for patient counselling and deciding on follow-up strategies.
참고문헌 (25)
- Cimbaluk D, "Uterine carcinosarcoma : immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets", Gynecol Oncol, 105, pp.138~144 (2007)
- Kurman RJ, "WHO classification of tumours of female reproductive organs" (2014), IARC Publications
- Mutch DG, "The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas", Gynecol Oncol, 3, pp.325~328 (2009)
- Galaal K, "Adjuvant radiotherapy and", or chemotherapy after surgery for uterine carcinosarcoma, 2013, pp.2013, CD006812~
- Keiko Saotome, "Impact of lymphadenectomy on the treatment of endometrial cancer using data from the JSOG cancer registry", Obstetrics & Gynecology Science, 64(1), pp.80~89 (2021), 대한산부인과학회[DOI]
- Rovirosa A, "Pathologic prognostic factors in stage I-III uterine carcinosarcoma treated with postoperative radiotherapy", Arch Gynecol Obstet, 290, pp.329~334 (2014)
- Abdulfatah E, "Predictive histologic factors in carcinosarcomas of the uterus : a multi-institutional study", Int J Gynecol Pathol, 38, pp.205~215 (2019)
- Cantrell LA, "Uterine carcinosarcoma : a review of the literature", Gynecol Oncol, 137, pp.581~588 (2015)
- Ferguson SE, "Prognostic features of surgical stage I uterine carcinosarcoma", Am J Surg Pathol, 31, pp.1653~1661 (2007)
- AlHilli MM, "Risk-scoring models for individualized prediction of overall survival in lowgrade and high-grade endometrial cancer", Gynecol Oncol, 133, pp.485~493 (2014)
- Balachandran VP, "Nomograms in oncology : more than meets the eye", Lancet Oncol, 16, pp.e173~80 (2015)
- Ouldamer L, "Predicting poor prognosis recurrence in women with endometrial cancer : a nomogram developed by the FRANCOGYN study group", Br J Cancer, 115, pp.1296~1303 (2016)
- Abu-Rustum NR, "A nomogram for predicting overall survival of women with endometrial cancer following primary therapy : toward improving individualized cancer care", Gynecol Oncol, 116, pp.399~403 (2010)
- Zivanovic O, "A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma", Cancer, 118, pp.660~669 (2012)
- Abu-Rustum NR, "Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma?", Am J Obstet Gynecol, 198, pp.457~ (2008)
- Capanu M, "Building a nomogram for surveyweighted cox models using R", J Stat Softw, 64, pp.1~17 (2015)
- Harrell FE Jr, "Evaluating the yield of medical tests", JAMA, 247, pp.2543~2546 (1982)
- Gonzalez Bosquet J, "The impact of multimodal therapy on survival for uterine carcinosarcomas", Gynecol Oncol, 116, pp.419~423 (2010)
- Chen X, "Uterine carcinosarcomas : clinical, histopathologic and immunohistochemical characteristics", Int J Gynecol Pathol, 36, pp.412~419 (2017)
- Harano K, "Prognostic factors in patients with uterine carcinosarcoma : a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group", Int J Clin Oncol, 21, pp.168~176 (2016)
- Crosbie EJ, "Body mass index, hormone replacement therapy, and endometrial cancer risk : a meta-analysis", Cancer Epidemiol Biomarkers Prev, 19, pp.3119~3130 (2010)
- Secord AA, "Body mass index and mortality in endometrial cancer : a systematic review and meta-analysis", Gynecol Oncol, 140, pp.184~190 (2016)
- Münstedt K, "Influence of body mass index on prognosis in gynecological malignancies", Cancer Causes Control, 19, pp.909~916 (2008)
- Van Cutsem E, "The causes and consequences of cancer-associated malnutrition", Eur J Oncol Nurs, 9(Suppl 2), pp.S51~S63 (2005)
- Leath CA 3rd, "Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma : implications for adjuvant therapy", Int J Gynecol Cancer, 19, pp.888~891 (2009)